GlassScriptPhysician profile
Veronica Sudekum
NPI 1295117653
$6,826.83
in general payments reported to CMS, 2019-2025
59 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 91% of Hospice and Palliative Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $171).
See the full distribution for Hospice and Palliative Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $110 · 2021: $314 · 2023: $2,528 · 2024: $1,754 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,119 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,119.28 |
| Education | $283.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $473.11 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Merck Sharp & Dohme LLC | $465.82 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $446.16 | 2021-2025 | Calquence, Lynparza |
| Pfizer INC. | $335.49 | 2023-2025 | |
| Janssen Biotech, INC. | $301.32 | 2023-2025 | Darzalex, Imbruvica, Tecvayli |
| Incyte Corporation | $265.93 | 2023-2025 | Jakafi, Niktimvo, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $243.65 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Alexion Pharmaceuticals, INC. | $237.11 | 2023-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $219.85 | 2023-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $219.50 | 2023-2024 | |
| Abbvie INC. | $218.08 | 2023-2025 | Venclexta |
| Seagen INC. | $189.06 | 2023 | Padcev, Tukysa, Adcetris |
| Genentech USA, INC. | $186.35 | 2023-2025 | Polivy, Phesgo, Lunsumio |
| Daiichi Sankyo INC. | $178.68 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Astellas Pharma US INC | $164.57 | 2023-2025 | Padcev, Xtandi, Xospata |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Sudekum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.